Construction of a HERG mutant L539fs/47-*558W pEGFP vector and the expression of the fusion protein in HEK293 cells

2013 ◽  
Vol 28 (4) ◽  
pp. 193-205
Author(s):  
Junbo ZHANG ◽  
Ying LÜ ◽  
Aifeng ZHANG ◽  
Chaofeng SUN ◽  
Wenqi HAN ◽  
...  
Keyword(s):  
2011 ◽  
Vol 1808 (12) ◽  
pp. 2819-2829 ◽  
Author(s):  
Jana Brejchová ◽  
Jan Sýkora ◽  
Kateřina Dlouhá ◽  
Lenka Roubalová ◽  
Pavel Ostašov ◽  
...  

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 3312-3312
Author(s):  
Rafi Kazi ◽  
Waitman Kurt Aumann ◽  
Pritha Bagchi ◽  
Donald Tope ◽  
Daniel S. Wechsler

Abstract Background: Leukemia is the most common type of childhood cancer. Although the prognosis for many pediatric leukemias has improved, leukemias associated with the t(10;11) CALM-AF10 translocation remain difficult to treat. CALM-AF10 leukemias account for ~5-10% of childhood T-cell acute lymphoblastic leukemia (T-ALL)as well as a subset of acute myeloid leukemia (AML). CALM-AF10 leukemias exhibit increased expression of proleukemic HOXA genes, but relatively little is known about the cellular mechanisms that drive CALM-AF10 leukemogenesis. Our laboratory has demonstrated that the CALM protein contains a nuclear export signal (NES) that is critical for CALM-AF10-dependent leukemogenesis. The NES interacts with the CRM1/XPO1 nuclear export receptor, which shuttles proteins from the nucleus to the cytoplasm through the nuclear pore complex. We have shown that transcriptional activation of HOXA genes by CALM-AF10 is dependent on its interaction with CRM1. Importantly, CRM1 does not contain a recognized DNA binding domain, and it is not currently understood how the CALM-AF10/CRM1 complex interacts with regulatory regions of HOXA genes. To identify proteins that mediate the interaction between the CALM-AF10/CRM1 complex and DNA, we took advantage of a proximity-based labeling approach using BioID2, a second-generation biotin ligase. When fused to a protein of interest and in the presence of biotin, BioID2 biotinylates proteins in close proximity to the ligase. These biotinylated proteins can then be identified by mass spectrometry (MS). Methods: We prepared an expression plasmid in which BioID2 was cloned in-frame with CALM-AF10. Human Embryonic Kidney 293 (HEK293) cells were transiently transfected with BioID2-CALM-AF10 and grown in the presence or absence of biotin. MS was performed to identify candidate interacting proteins. We validated direct interactions of candidate proteins with CALM-AF10 using co-immunoprecipitation experiments in HEK293 cells transfected with a CALM-AF10 plasmid. We confirmed that candidate proteins are present in murine CALM-AF10 leukemia cells via Western blotting. In order to efficiently knockout (KO) candidate proteins, we have generated a human U937 cell line (which harbors a t(10;11) CALM-AF10 translocation) with a stable incorporated Cas9. To assess whether KO of EPS15, DVL2 or CTTN affects HOXA5 expression, we performed RT-qPCR in U937-Cas9 cells lines with confirmed KO. Results: We carried out three independent transfections/MS experiments, which identified 71, 95 and 61 proteins, respectively. Of the proteins identified, 12 candidates were common to all three experiments . Importantly, we identified Disruptor Of Telomeric silencing 1-Like (DOT1L), a protein known to interact with AF10, and Nuclear pore complex protein 214 (NUP214), a protein that interacts with CRM1 and that is involved in leukemogenic translocations. We chose EPS15, DVL2 and CTTN for further study, as each of these proteins plays a role in leukemogenesis. We performed initial validation of direct interactions via co-immunoprecipitation and found that all three proteins co-precipitate with CALM-AF10. Western blotting showed that all three proteins are expressed in a murine CALM-AF10 leukemia cell line. We effectively knocked out EPS15 protein expression in U937 cells, and showed that HOXA5 expression is reduced in the setting of EPS15 knockout. Conclusion: We used biotin ligase-dependent proximity-based labeling to identify candidate proteins that potentially interact with the CALM-AF10 fusion protein. Our identification of DOT1L validates the approach, since DOT1L is known to interact with CALM-AF10. We have started to investigate three candidate proteins - EPS15, DVL2 and CTTN - all of which are involved in leukemogenic transformation. We have shown that EPS15, DVL2 and CTTN are expressed in murine CALM-AF10 leukemia cells and directly interact with the CALM-AF10 fusion protein. Knockout of EPS15 in U937 cells results in decreased HOXA5 expression, suggesting the importance of EPS15 in CALM-AF10 leukemogenesis. Evaluation of the roles of these proteins in leukemogenesis may lead to identification of novel pathways involved in CALM-AF10 leukemogenesis. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5364-5364
Author(s):  
Volker Rainer Stoldt ◽  
Abdelouahid El Khattouti ◽  
Rudiger E. Scharf

Abstract The HPA-1 polymorphism of platelet integrin αIIbβ3 (GPIIb-IIIa) arises from a thymidine to cytosine transition in position 1565 of the ITGB3 gene. This transition leads to an amino acid exchange at residue 33 of the mature β3 subunit. The resulting isoforms are HPA-1a (Leu33) or HPA-1b (Pro33). We have shown that the HPA-1b variant of αIIbβ3 is associated with premature manifestation of myocardial infarction in patients suffering from coronary artery disease (Zotz et al. J Thromb Haemost 2005). This observation has lead to the hypothesis that the HPA-1b variant of αIIbβ3 may increase platelet thrombogenicity. Recently, we have also demonstrated that HPA-1b/1b platelets adhering onto fibrinogen are more resistant than HPA-1a/1a platelets when exposed to arterial shear rates of 1000 to 1500 sec-1 (Loncar et al. Thromb J 2007). To explore the molecular nature of the postulated prothrombotic phenotype of HPA-1b in further detail, we have now overexpressed the yellow fluorescent protein (YFP) or the cyan fluorescent protein (CFP) fused to the cytoplasmic tails of the αIIb or β3 subunit of both αIIbβ3 variants in human embryonic kidney-293 (HEK293) cells. Clones were screened for their cyan and yellow fluorescence. Ten positive clones of each αIIbβ3 variant were detected and characterized by Western blotting identifying the 140 kD αIIb-CFP fusion protein and the 113 kD β3-YFP fusion protein with appropriate antibodies directed against the αIIb subunit, the β3 subunit or the fluorescent proteins. Stable HEK293 clones expressing the HPA-1 receptor isoforms on the cell surface were functionally analyzed by flow cytometry (Becton Dickinson), confocal laser scanning microscopy (Zeiss), and a fluorescence imager (Thermo). We used fluorophore (PE)-conjugated complex-specific (PM6/248) and activation-dependent (PAC-1) antibodies and fluorescently tagged fibrinogen (Alexa647- Fg) in combination with phorbol-12-myristate-13-acetate (PMA) or organic acid (1-stearoyl-2-arachidonoyl-sn-glycerol, SAG). Corresponding controls were performed with the chimeric antibody abciximab (ReoPro) to block fibrinogen binding to αIIbβ3 or with pertussis toxin (PTX) to inhibit G-protein-coupled inside-out signal transduction. Functional integrity of the integrin variants (HPA-1a and HPA-1b) was demonstrated by intact activation through G-protein-coupled receptors with SAG and by specific binding of Alexa647 fibrinogen to αIIbβ3 indicating proper insertion of the receptor complex into the plasma membrane of transfected cells. In the presence of PTX or abciximab, activation and ligand binding function of αIIbβ3 were completely (>95%) inhibited in both isoforms of HPA-1. Cytoplasmic conformational changes upon integrin activation using either PMA or SAG were followed by fluorescence resonance energy transfer (FRET) and quantified by FRET signal disappearance due to allosteric changes of the cytoplasmic domains. Stimulation with PMA and SAG caused FRET signal disappearance to same extent in each HPA-1 variant. However, the dynamics of signal disappearance appeared to be faster in the HPA-1b than in the HPA-1a variant of the cell clones studied so far. This observation corresponds to the prothrombotic phenotype of HPA-1b. In conclusion, our results demonstrate that we have generated a cellular model which can be useful to study molecular properties of αIIbβ3 variants and to explore the nature of the prothrombotic HPA-1b phenotype in further detail.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 5126-5126
Author(s):  
Robert L. Redner ◽  
Anuja Chattopadhyay ◽  
Brian L. Hood ◽  
Thomas P. Conrads

Abstract Abstract 5126 The t(5;17)(q35;q21) variant of Acute Promyelocytic Leukemia fuses nucleophosmin (NPM) to the retinoic acid receptor alpha (RARA). The resultant NPM-RAR fusion protein blocks myeloid differentiation, and leads to a leukemic phenotype similar to that caused by the t(15;17)(q22;q21) PML-RAR fusion. The contribution of the N-terminal 117 amino acids of NPM contained within NPM-RAR has not been well studied. NPM is a molecular chaperone, and binds to a variety of proteins implicated in leukemogenesis. We performed a proteomic analysis to identify NPM-RAR interacting proteins. Vectors encoding NPM-RAR or RARA (as control) fused in frame to calmodulin binding peptide and Protein A were expressed in HEK293 cells, and interacting proteins subjected to tryptic digest. Peptides were analyzed by nanoflow reversed-phase liquid chromatography-mass spectrometry. Amongst other targets, we identified tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD) as a distinct binding partner for NPM-RAR. TRADD did not bind to wild-type RARA or NPM, suggesting that the interaction was unique to the fusion protein. The NPM-RAR/TRADD interaction was verified by reciprocal co-precipitation. Though NPM-RAR localizes primarily in the nucleoplasm, we also found a low level of NPM-RAR/TRADD dimer in the cytoplasm utilizing confocal microscopy. Expression of NPM-RAR in U937 cells impaired TNF activation of caspase 8 and caspase 3. TNF-induced acquisition of Annexin V, generation of sub-G0/G1 nuclear content, and cleavage of PARP were all blunted, indicating that NPM-RAR blocks TNF-induced apoptosis. Our studies identify a novel mechanism through which NPM-RAR impacts leukemogenesis. Disclosures: No relevant conflicts of interest to declare.


2010 ◽  
Vol 42 (3) ◽  
pp. 230-235 ◽  
Author(s):  
L. Sun ◽  
X. Shen ◽  
Y. Liu ◽  
G. Zhang ◽  
J. Wei ◽  
...  

2007 ◽  
Vol 292 (5) ◽  
pp. C1895-C1905 ◽  
Author(s):  
Emmanuel M. Awumey ◽  
Allyn C. Howlett ◽  
James W. Putney ◽  
Debra I. Diz ◽  
Richard D. Bukoski

The rat dorsal root ganglion (DRG) Ca2+-sensing receptor (CaR) was stably expressed in-frame as an enhanced green fluorescent protein (EGFP) fusion protein in human embryonic kidney (HEK)293 cells, and is functionally linked to changes in intracellular Ca2+ concentration ([Ca2+]i). RT-PCR analysis indicated the presence of the message for the DRG CaR cDNA. Western blot analysis of membrane proteins showed a doublet of 168–175 and 185 kDa, consistent with immature and mature forms of the CaR.EGFP fusion protein, respectively. Increasing extracellular [Ca2+] ([Ca2+]e) from 0.5 to 1 mM resulted in increases in [Ca2+]i levels, which were blocked by 30 μM 2-aminoethyldiphenyl borate. [Ca2+]e-response studies indicate a Ca2+ sensitivity with an EC50 of 1.75 ± 0.10 mM. NPS R-467 and Gd3+ activated the CaR. When [Ca2+]e was successively raised from 0.25 to 4 mM, peak [Ca2+]i, attained with 0.5 mM, was reduced by ∼50%. Similar reductions were observed with repeated applications of 10 mM Ca2+, 1 and 10 μM NPS R-467, or 50 and 100 μM Gd3+, indicating desensitization of the response. Furthermore, Ca2+ mobilization increased phosphorylated protein kinase C (PKC)α levels in the cells. However, the PKC activator, phorbol myristate acetate did not inhibit CaR-mediated Ca2+ signaling. Rather, a spectrum of PKC inhibitors partially reduced peak responses to Cae2+. Treatment of cells with 100 nM PMA for 24 h, to downregulate PKC, reduced [Ca2+]i transients by 49.9 ± 5.2% (at 1 mM Ca2+) and 40.5 ± 6.5% (at 2 mM Ca2+), compared with controls. The findings suggest involvement of PKC in the pathway for Ca2+ mobilization following CaR activation.


2006 ◽  
Vol 46 (2) ◽  
pp. 321-331 ◽  
Author(s):  
Johan Öhman ◽  
Emma Jakobsson ◽  
Ulla Källström ◽  
Annette Elmblad ◽  
Akbar Ansari ◽  
...  

2002 ◽  
Vol 7 (3) ◽  
pp. 281-289
Author(s):  
Renée S. Martin ◽  
Paul H. Reynen ◽  
Joyce J. Calixto ◽  
Christian L. Reyes ◽  
Thomas K. Chang ◽  
...  

The pharmacology of G protein-coupled receptors is widely accepted to depend on the G protein subunit to which the agonist-stimulated receptor couples. In order to investigate whether CB1 agonist-mediated signal transduction via an engineered Gaα16 system is different than that of the Gi/o coupling normally preferred by the CB1 receptor, we transfected the human recombinant CB1 receptor (hCB1) or a fusion protein comprising the hCB1 receptor and Gα16 (hCB1-Gα16) into HEK293 cells. From competition binding studies, the rank order of ligand affinities at the hCB1-Gaα16 fusion protein was found to be similar to that for hCB1: HU 210 > CP 55,940 ≥ SR 141716A > WIN 55212-2 > anandamide > JWH 015. Agonists increased [35S]GTPγS binding or inhibited forskolin-stimulated cAMP, presumably by coupling to Gi/o, in cells expressing hCB1 but not hCB1-Gα16. However, an analogous rank order of potencies was observed for these agonists in their ability to evoke increases in intracellular calcium concentration in cells expressing hCBq-Gaα16 but not hCB1. These data demonstrate that ligand affinities for the hCB1, receptor are not affected by fusion to the Gα16 subunit. Furthermore, there is essentially no difference in the function of the hCB1, receptor when coupled to Gi/o, or Gα16.


Sign in / Sign up

Export Citation Format

Share Document